Vistin Pharma ASA (OSL: VISTN)
Norway
· Delayed Price · Currency is NOK
23.40
-0.30 (-1.27%)
Jan 3, 2025, 9:00 AM CET
Vistin Pharma ASA Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Operating Revenue | 423.59 | 435.39 | 287.68 | 275.81 | 253.16 | 227.19 | Upgrade
|
Other Revenue | 2.94 | 2.94 | 17.18 | 2.81 | 0.75 | 0.94 | Upgrade
|
Revenue | 426.52 | 438.33 | 304.85 | 278.62 | 253.91 | 228.13 | Upgrade
|
Revenue Growth (YoY) | -2.74% | 43.78% | 9.41% | 9.73% | 11.30% | 13.77% | Upgrade
|
Cost of Revenue | 148.95 | 176.64 | 138.06 | 96.1 | 73.29 | 84.11 | Upgrade
|
Gross Profit | 277.57 | 261.68 | 166.79 | 182.53 | 180.62 | 144.02 | Upgrade
|
Selling, General & Admin | 84.23 | 81.84 | 69.73 | 64.96 | 64.34 | 61.09 | Upgrade
|
Other Operating Expenses | 91.73 | 93.9 | 90.88 | 73.71 | 61.1 | 57.2 | Upgrade
|
Operating Expenses | 194.91 | 193.09 | 172.88 | 149.28 | 135.06 | 127.25 | Upgrade
|
Operating Income | 82.67 | 68.6 | -6.1 | 33.25 | 45.56 | 16.77 | Upgrade
|
Interest Expense | -7.21 | -2.27 | -2.14 | -0.36 | -0.82 | -0.22 | Upgrade
|
Interest & Investment Income | 11.31 | 0.22 | 0.03 | 0.27 | 1.72 | 3.87 | Upgrade
|
Currency Exchange Gain (Loss) | -7.92 | -7.92 | 2.51 | -1.13 | -23.84 | 0.61 | Upgrade
|
Other Non Operating Income (Expenses) | -0.11 | -0.11 | -0.31 | -0.03 | -146.89 | 63.01 | Upgrade
|
EBT Excluding Unusual Items | 78.74 | 58.52 | -6.01 | 32 | -124.27 | 84.04 | Upgrade
|
Pretax Income | 78.74 | 58.52 | -6.01 | 32 | -124.27 | 84.04 | Upgrade
|
Income Tax Expense | 17.37 | 12.92 | -1.29 | 7.13 | -27.32 | 17.97 | Upgrade
|
Earnings From Continuing Operations | 61.37 | 45.6 | -4.72 | 24.87 | -96.96 | 66.08 | Upgrade
|
Earnings From Discontinued Operations | - | - | - | - | - | 0.13 | Upgrade
|
Net Income | 61.37 | 45.6 | -4.72 | 24.87 | -96.96 | 66.2 | Upgrade
|
Net Income to Common | 61.37 | 45.6 | -4.72 | 24.87 | -96.96 | 66.2 | Upgrade
|
Net Income Growth | 37.89% | - | - | - | - | - | Upgrade
|
Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 44 | 44 | Upgrade
|
Shares Outstanding (Diluted) | 44 | 44 | 44 | 44 | 44 | 44 | Upgrade
|
Shares Change (YoY) | - | - | - | - | - | 25.81% | Upgrade
|
EPS (Basic) | 1.38 | 1.03 | -0.11 | 0.56 | -2.19 | 1.49 | Upgrade
|
EPS (Diluted) | 1.38 | 1.03 | -0.11 | 0.56 | -2.19 | 1.49 | Upgrade
|
EPS Growth | 37.89% | - | - | - | - | - | Upgrade
|
Free Cash Flow | 55.77 | 72.69 | -74.8 | -18.26 | -198.83 | 0.58 | Upgrade
|
Free Cash Flow Per Share | 1.26 | 1.64 | -1.69 | -0.41 | -4.48 | 0.01 | Upgrade
|
Dividend Per Share | 1.000 | 1.000 | 0.750 | 0.750 | 0.500 | 1.000 | Upgrade
|
Dividend Growth | 33.33% | 33.33% | 0% | 50.00% | -50.00% | - | Upgrade
|
Gross Margin | 65.08% | 59.70% | 54.71% | 65.51% | 71.14% | 63.13% | Upgrade
|
Operating Margin | 19.38% | 15.65% | -2.00% | 11.93% | 17.94% | 7.35% | Upgrade
|
Profit Margin | 14.39% | 10.40% | -1.55% | 8.92% | -38.19% | 29.02% | Upgrade
|
Free Cash Flow Margin | 13.08% | 16.58% | -24.54% | -6.55% | -78.31% | 0.25% | Upgrade
|
EBITDA | 100.56 | 84.89 | 5.33 | 42.79 | 54.28 | 24.16 | Upgrade
|
EBITDA Margin | 23.58% | 19.37% | 1.75% | 15.36% | 21.38% | 10.59% | Upgrade
|
D&A For EBITDA | 17.89 | 16.3 | 11.43 | 9.54 | 8.73 | 7.39 | Upgrade
|
EBIT | 82.67 | 68.6 | -6.1 | 33.25 | 45.56 | 16.77 | Upgrade
|
EBIT Margin | 19.38% | 15.65% | -2.00% | 11.93% | 17.94% | 7.35% | Upgrade
|
Effective Tax Rate | 22.06% | 22.08% | - | 22.28% | - | 21.38% | Upgrade
|
Revenue as Reported | 438.33 | 438.33 | 304.85 | 278.62 | 253.91 | 228.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.